oncgnostics GmbH
The oncgnostics GmbH, a spin-off of the University Hospital Jena, is a company working on molecular diagnostics with main focus on the development of in-vitro diagnostics based on epigenetic biomarkers.
oncgnostics GmbH is working according to ISO 13485 standards in research, development, production and management.
Recent Posts
Contact
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena
Germany
Phone: +49 (0)3641 5548500
Email: contact[at]oncgnostics.com
Internet: www.oncgnostics.com
Oncgnostics receives award: Germany’s most innovative companies
BlogThe business magazine Capital selected Germany’s most innovative companies for the third time. Oncgnostics GmbH made it into the selection. The biotech company scored particularly well in the evaluation criterion […]
A startup turns 10 – oncgnostics grows with its employees
Blog10 years ago a small, very motivated team founded the oncgnostics GmbH to improve cervical cancer screening. Since then, oncgnostics GmbH has been growing and with it the number of […]
Cancer prevention remains a matter of the heart: Biotech company oncgnostics celebrates 10th anniversary
Press ReleasesThe company oncgnostics GmbH, founded in 2012, already launched its first product in 2015: the diagnostic test for cervical cancer “GynTect”. This is now sold in over ten countries in […]
Third Generation Sequencing: Detecting cancer at DNA level
BlogDr. Carolin Dippmann and Daria Meyer from our research and development team work, among other things, with the “third-generation sequencing” method. With the help of this technology, they are examining […]
That was 2021 – and here’s what happens next
BlogWe look back on the milestones of 2021 – and forward to upcoming projects. In May, we moved the entire company within Jena, thus gaining space for more office workspace […]
Ovarian cancer: The silent danger
BlogEvery year, about 7,300 women in Germany are diagnosed with ovarian cancer (ovarian carcinoma), and more than 5,000 die of the consequences. This means that one in 72 women will […]
Epigenetic markers – definition and significance for early cancer detection
BlogAs a biotechnology company, we have been researching cancer diagnostics on a molecular basis since 2012. We deal with epigenetic markers, which help us to recognise cancers, such as cervical […]
Pilot study: Cancer screening from home is possible
Press ReleasesA large proportion of women who develop cervical cancer in high-income countries such as Germany do not regularly attend screening. This is particularly alarming, as cancer screenings have become much […]
Step USA – our virtual business trip
BlogWhat has to be considered if you want to start as a German biotech company on the American market? What are the legal bases and challenges there? We got an […]
Positive HPV test: What now?
BlogSince the beginning of 2020, when early cervical cancer screening in Germany was supplemented by a routine HPV test for women over 35, more people have been confronted with a […]